DE69010206T2 - Stabilisierte protein- oder peptidkonjugate. - Google Patents

Stabilisierte protein- oder peptidkonjugate.

Info

Publication number
DE69010206T2
DE69010206T2 DE69010206T DE69010206T DE69010206T2 DE 69010206 T2 DE69010206 T2 DE 69010206T2 DE 69010206 T DE69010206 T DE 69010206T DE 69010206 T DE69010206 T DE 69010206T DE 69010206 T2 DE69010206 T2 DE 69010206T2
Authority
DE
Germany
Prior art keywords
protein
peptide
peptide conjugates
vivo
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69010206T
Other languages
English (en)
Other versions
DE69010206D1 (de
Inventor
Per-Ake Nygren
Hans Wigzell
Mathias Uhlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affibody AB
Original Assignee
CEMU Bioteknik AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CEMU Bioteknik AB filed Critical CEMU Bioteknik AB
Publication of DE69010206D1 publication Critical patent/DE69010206D1/de
Application granted granted Critical
Publication of DE69010206T2 publication Critical patent/DE69010206T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69010206T 1989-08-01 1990-07-31 Stabilisierte protein- oder peptidkonjugate. Expired - Lifetime DE69010206T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8902638A SE509359C2 (sv) 1989-08-01 1989-08-01 Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
PCT/SE1990/000509 WO1991001743A1 (en) 1989-08-01 1990-07-31 Stabilized protein or peptide conjugates

Publications (2)

Publication Number Publication Date
DE69010206D1 DE69010206D1 (de) 1994-07-28
DE69010206T2 true DE69010206T2 (de) 1994-10-13

Family

ID=20376608

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69010206T Expired - Lifetime DE69010206T2 (de) 1989-08-01 1990-07-31 Stabilisierte protein- oder peptidkonjugate.

Country Status (8)

Country Link
EP (1) EP0486525B1 (de)
JP (1) JP3477196B2 (de)
AT (1) ATE107514T1 (de)
AU (1) AU652124B2 (de)
CA (1) CA2064689C (de)
DE (1) DE69010206T2 (de)
SE (1) SE509359C2 (de)
WO (1) WO1991001743A1 (de)

Families Citing this family (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
CA2184002A1 (en) * 1994-02-23 1995-08-31 Jeffrey M. Blaney Method and compositions for increasing the serum half-life of pharmacologically active agents
FR2726471B1 (fr) 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US20020193571A1 (en) * 1996-01-08 2002-12-19 Paul J. Carter Wsx receptor agonist antibodies
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
DE69942578D1 (de) 1998-05-22 2010-08-26 Univ R Bifunktionelle moleküle sowie darauf basierende therapien.
JP2002534059A (ja) 1998-10-13 2002-10-15 ザ ユニバーシティ オブ ジョージア リサーチファウンデーション，インコーポレイティド 安定化された生物活性ペプチドおよび同定、合成および使用方法
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
WO2001035978A1 (en) 1999-11-19 2001-05-25 The Board Of Trustees Of The Leland Stanford Junior University Targeted bifunctional molecules and therapies based thereon
AU2043901A (en) * 1999-11-19 2001-05-30 Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules having modulated pharmacokinetic properties and therapies based thereon
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
EP1757701A1 (de) * 1999-12-24 2007-02-28 Genentech, Inc. Verfahren und Zusammensetzungen zur Verlängerung der Halbzeiten der Entfernung von biowirksamen Verbindungen
US7608681B2 (en) * 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
EP2075256A2 (de) 2002-01-14 2009-07-01 William Herman Gezielte Liganden
JP2005521733A (ja) 2002-03-26 2005-07-21 ダイアックス、コープ フィブリノーゲン結合部分
EP1837031B1 (de) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methoden und Kompositionen um Diabetes zu behandeln
ATE328906T1 (de) * 2002-06-28 2006-06-15 Domantis Ltd Dual-specifische liganden mit erhöhter halbwertszeit
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP3299393A1 (de) 2002-11-08 2018-03-28 Ablynx N.V. Gegen den tumornekrosefaktor-alpha gerichtete antikörper mit einfacher domäne und verwendungen dafür
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
EP2380594B1 (de) * 2004-04-06 2019-12-04 Affibody AB Verwendung eines serumalbumin-bindenden peptide zur reduzierung des immunogenität eines proteins
WO2005118642A2 (en) 2004-06-01 2005-12-15 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
MX2007003907A (es) * 2004-10-05 2007-05-21 Genentech Inc Agentes terapeuticos con toxicidad reducida.
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
MX2007006593A (es) * 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
KR20070094909A (ko) * 2004-12-02 2007-09-27 도만티스 리미티드 혈청 알부민 및 ｇｌｐ-1 또는 ｐｙｙ를 표적으로 삼는이중특이성 도메인을 갖는 항체
MX2007006602A (es) * 2004-12-02 2007-12-10 Domantis Ltd Peptidos de dominio plad con vida media en suero aumentada debido a conjugacion con anticuerpos de dominio.
PL1888641T3 (pl) 2005-05-18 2012-05-31 Ablynx Nv Białka wiążące albuminę surowicy
JP2009511545A (ja) * 2005-10-14 2009-03-19 ノボ・ノルデイスク・エー／エス Ｉｌ−１インヒビターを使用する糖尿病の治療
CN101528767A (zh) * 2006-10-11 2009-09-09 埃博灵克斯股份有限公司 以基本不依赖pH的方式结合血清蛋白的氨基酸序列、包括其的化合物、及其用途
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2514767A1 (de) 2006-12-19 2012-10-24 Ablynx N.V. Gegen Metalloproteinase der ADAM-Familie gerichtete Aminosäuren und Polypeptide damit zur Behandlung von Erkrankungen und Störungen im Zusammenhang mit ADAM
EP2115004A2 (de) 2006-12-19 2009-11-11 Ablynx N.V. Gegen gpcrs gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit gpcr in zusammenhang tehenden krankheiten und erkrankungen
DK2190863T3 (en) 2007-07-31 2015-11-30 Affibody Ab New albumin binding compositions, methods and uses
CN101842387B (zh) 2007-09-26 2014-05-07 Ucb医药有限公司 双特异性抗体融合物
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
US8975382B2 (en) 2007-11-27 2015-03-10 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
EP2077272A1 (de) 2007-12-21 2009-07-08 Affibody AB Polypeptid-Bibliothek mit vorbestimmtem Gerüst
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (de) 2007-12-21 2009-06-24 Affibody AB Neue Polypeptide mit Bindungsaffinität für HER2
CN102056945A (zh) 2008-04-07 2011-05-11 埃博灵克斯股份有限公司 针对Notch途径的单可变结构域
CN102099378B (zh) 2008-05-16 2016-01-20 埃博灵克斯股份有限公司 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽
SI2285408T1 (sl) 2008-06-05 2019-02-28 Ablynx N.V. Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
CN105601745B (zh) 2008-09-26 2020-09-08 Ucb医药有限公司 生物产品
EP4104821A1 (de) 2008-10-29 2022-12-21 Ablynx N.V. Formulierungen von einzeldomänen-antigen-bindenden molekülen
US10118962B2 (en) 2008-10-29 2018-11-06 Ablynx N.V. Methods for purification of single domain antigen binding molecules
CA2747644C (en) 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
CA2758191C (en) 2009-04-10 2015-06-30 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
AU2010230311B9 (en) 2009-04-27 2012-09-20 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the IL-12 receptore betal subunit
CA2993053A1 (en) 2009-04-27 2010-11-04 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
ES2643034T3 (es) 2009-06-05 2017-11-21 Ablynx N.V. Construcciones de Nanobody contra el virus respiratorio sincicial humano (VRSH) trivalentes para la prevención y/o el tratamiento de infecciones de las vías respiratorias
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
JP5960598B2 (ja) 2009-11-04 2016-08-02 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
EP2516458A1 (de) 2009-12-22 2012-10-31 Novartis AG Tetravalentes fusionsprotein einer konstanten cd47-antikörperregion für therapiezwecke
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
RU2012151296A (ru) * 2010-04-30 2014-06-10 Санва Кагаку Кенкюсо Ко., Лтд Пептид для улучшения биостабильности биоактивного вещества и биоактивное вещество, имеющее повышенную биостабильность
RU2012149227A (ru) 2010-05-20 2014-06-27 Аблинкс Нв Биологические материалы, относящиеся к her3
EP2933262B1 (de) 2010-07-09 2018-05-02 Affibody AB Polypeptide
CN103370083B (zh) 2010-09-28 2016-11-16 艾米琳制药有限责任公司 具有增强的作用持续时间的工程化多肽
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
EP2625203A1 (de) 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1-antikörper und ihre verwendung zur behanldung von autoimmun- und entzündungserkrankungen
EA202092589A3 (ru) 2010-11-08 2021-06-30 Аблинкс Н.В. Cxcr2-связывающие полипептиды
KR20140032356A (ko) 2010-11-26 2014-03-14 몰리큘라 파트너스 아게 설계된 안키린 반복 단백질에 대한 개선된 n-말단 캡핑 모듈
WO2012109624A2 (en) 2011-02-11 2012-08-16 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
CA2831415A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Bispecific anti-cxcr7 immunoglobulin single variable domains
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
ES2657862T3 (es) 2011-05-13 2018-03-07 Gamamabs Pharma Anticuerpos contra HER3
US9505840B2 (en) 2011-05-27 2016-11-29 Ablynx N.V. Inhibition of bone resorption with RANKL binding peptides
JP2014519338A (ja) 2011-06-16 2014-08-14 ノバルティス アーゲー 治療薬として使用される可溶性タンパク質
US9249228B2 (en) 2011-06-22 2016-02-02 Oribase Pharma Anti-Axl antibodies and uses thereof
EP2723377B1 (de) 2011-06-22 2018-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl-antikörper und verwendungen damit
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
PT2726099T (pt) 2011-07-01 2018-11-13 Novartis Ag Método para o tratamento de distúrbios metabólicos
WO2013043071A1 (en) 2011-09-23 2013-03-28 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Modified albumin-binding domains and uses thereof to improve pharmacokinetics
AU2012310328A1 (en) 2011-09-23 2014-04-10 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Anti-Tumor Necrosis Factor-alpha agents and uses thereof
DK2747782T3 (en) 2011-09-23 2018-04-23 Ablynx Nv Long-term inhibition of interleukin-6-mediated signal transmission
WO2013045707A2 (en) 2011-09-30 2013-04-04 Ablynx Nv Biological materials related to c-met
DK2776466T3 (da) 2011-11-11 2017-11-20 Ucb Biopharma Sprl Albuminbindende antistoffer og bindingsfragmenter deraf
DK2817329T3 (en) 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polypeptides Binding to Human Complement Component C5.
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
WO2013143890A1 (en) 2012-03-28 2013-10-03 Affibody Ab Oral administration
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
CN111763247A (zh) 2012-09-25 2020-10-13 阿菲博迪公司 白蛋白结合多肽
CN104768976B (zh) 2012-10-05 2020-09-22 阿菲博迪公司 Her3结合多肽
JP6382826B2 (ja) 2012-10-25 2018-08-29 アフィボディ・アーベー アルブミン結合ポリペプチド
WO2014064238A1 (en) 2012-10-25 2014-05-01 Affibody Ab Method for the separation of proteins containing an albumin-binding
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
EP2752426A1 (de) 2013-01-03 2014-07-09 Covagen AG Humane Serumalbumin bindende Verbindungen und Fusionsproteine daraus
CU24300B1 (es) 2013-02-08 2017-12-08 Novartis Ag Anticuerpos anti-il-17a útiles en el tratamiento de trastornos autoinmunes e inflamatorios
EP2968587A2 (de) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Serumalbumingebundene fibronectin-gerüstdomänen oder daran bindendes element
WO2014210029A1 (en) 2013-06-24 2014-12-31 Riogin Corporation Double binding constructs
US20160200818A1 (en) 2013-08-14 2016-07-14 Novartis Ag Methods of treating Sporadic Inclusion Body Myositis
CN116987154A (zh) 2013-08-28 2023-11-03 阿菲博迪公司 具有突变的支架的结合多肽
PT3038633T (pt) 2013-08-28 2021-01-14 Ipc Res Llc Polipéptidos estáveis que se ligam ao complemento humano c5
CN105849125B (zh) 2013-11-07 2020-05-15 国家医疗保健研究所 神经调节蛋白变构抗her3抗体
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
EP3161001A2 (de) 2014-06-25 2017-05-03 Novartis AG Il17-a spezifische antikörper die mit hyaluronan bindenden peptid-marker fusioniert sind
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
CA2969307A1 (en) * 2014-12-04 2016-06-09 Novartis Ag Methods and compositions using klotho variant polypeptides
US10493135B2 (en) 2014-12-19 2019-12-03 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
EP4272838A3 (de) 2015-04-02 2024-01-10 Molecular Partners AG Konstruierte ankyrin-repeat-domänen mit bindungsspezifität für serumalbumin
EP3277316A1 (de) 2015-04-02 2018-02-07 Ablynx N.V. Bispezifische cxcr4-cd-4-polypeptide mit starker anti-hiv-wirkung
ES2754427T3 (es) 2015-05-13 2020-04-17 Ablynx Nv Polipéptidos de reclutamiento de células T basados en la reactividad de TCR alfa/beta
CN107847559B (zh) 2015-05-13 2022-07-01 埃博灵克斯股份有限公司 基于cd3反应性的t细胞募集多肽
US10526415B2 (en) 2015-05-22 2020-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the Cath-D catalytic activity and its binding to the LRP1 receptor
JP6983075B2 (ja) 2015-06-02 2021-12-17 ノヴォ ノルディスク アー／エス 極性の組換え延長部を有するインスリン
EP3328429A4 (de) 2015-07-31 2019-03-20 The Research Institute at Nationwide Children's Hospital Peptide und antikörper zur beseitigung von biofilmen
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
DK3368571T3 (da) 2015-10-30 2023-01-23 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
RU2018122255A (ru) 2015-11-27 2019-12-19 Аблинкс Нв Полипептиды, ингибирующие cd40l
EP3471747A1 (de) 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von myointimaler proliferation
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
US11186634B2 (en) 2016-07-29 2021-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies targeting tumor associated macrophages and uses thereof
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
AU2017319702A1 (en) 2016-09-02 2019-04-11 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
BR112019005587A2 (pt) 2016-09-22 2019-06-11 Molecular Partners Ag proteínas de ligação recombinantes e sua utilização
JP7222888B2 (ja) 2016-11-16 2023-02-15 アブリンクス エン．ヴェー． Ｃｄ１２３及びｔｃｒアルファ／ベータに結合することが可能なｔ細胞動員ポリペプチド
WO2018129078A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
EP3565834A1 (de) 2017-01-04 2019-11-13 The Research Institute at Nationwide Children's Hospital Antikörperfragmente zur behandlung von biofilmbedingten erkrankungen
CN110392697A (zh) 2017-03-02 2019-10-29 国家医疗保健研究所 对nectin-4具有特异性的抗体及其用途
US11746136B2 (en) 2017-03-15 2023-09-05 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
AU2018240117A1 (en) 2017-03-24 2019-09-19 Beth Israel Deaconess Medical Center, Inc. Methods for preventing and treating heart disease
EP3606560A2 (de) 2017-04-05 2020-02-12 Novo Nordisk A/S Oligomererweiterte insulin-fc-konjugate
AU2018277310A1 (en) 2017-06-02 2019-12-12 Ablynx Nv Aggrecan binding immunoglobulins
US20200190216A1 (en) 2017-06-02 2020-06-18 Merck Patent Gmbh Mmp13 binding immunoglobulins
TWI826376B (zh) 2017-06-02 2023-12-21 德商麥克專利有限公司 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
EP3630847A1 (de) 2017-06-02 2020-04-08 Merck Patent GmbH Adamts-bindende immunoglobuline
EP3645564A1 (de) 2017-06-28 2020-05-06 Novartis AG Verfahren zur prävention und behandlung von harninkontinenz
JP2020532285A (ja) 2017-07-11 2020-11-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
US20200263153A1 (en) 2017-09-27 2020-08-20 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
BR112020006999A2 (pt) 2017-10-10 2020-10-06 Numab Therapeutics AG anticorpo multiespecífico, composição farmacêutica e método de produção
EP3470426A1 (de) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispezifischer antikörper
EP3552631A1 (de) 2018-04-10 2019-10-16 Inatherys Antikörper-arzneimittel-konjugate und deren verwendungen zur behandlung von krebs
AU2019271149B2 (en) 2018-05-14 2023-07-13 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
JP7460609B2 (ja) 2018-05-14 2024-04-02 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン－２ポリペプチド及びその使用方法
SG11202101038SA (en) 2018-08-01 2021-02-25 Imcheck Therapeutics Sas Anti-btn3a antibodies and their use in treating cancer or infectious disorders
US20220047701A1 (en) 2018-09-10 2022-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of her2/neu antibody with heme for treating cancer
WO2020069398A1 (en) 2018-09-27 2020-04-02 Akrevia Therapeutics Inc. Masked cytokine polypeptides
US20210338783A1 (en) 2018-10-05 2021-11-04 Research Institute At Nationwide Children's Hospital Compositions and methods for enzymatic disruption of bacterial biofilms
WO2020193520A1 (en) 2019-03-25 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
MX2021013766A (es) 2019-05-14 2022-02-21 Werewolf Therapeutics Inc Restos de separacion y metodos de uso de los mismos.
AU2020291821A1 (en) 2019-06-12 2022-01-06 Novartis Ag Natriuretic Peptide Receptor 1 antibodies and methods of use
EP3997120A4 (de) 2019-07-08 2023-11-22 Research Institute at Nationwide Children's Hospital Antikörperzusammensetzungen zur unterbrechung von biofilmen
EP3785726A1 (de) 2019-09-02 2021-03-03 Biotest AG Faktor-viii-protein mit erhöhter halbwertszeit
WO2021043757A1 (en) 2019-09-02 2021-03-11 Biotest Ag Factor viii protein with increased half-life
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
CN114450304B (zh) 2019-09-27 2023-12-12 国家医疗保健研究所 抗苗勒管抑制物质抗体及其用途
CN115175680A (zh) 2019-10-18 2022-10-11 加利福尼亚大学董事会 Plxdc激活剂及其用于治疗血管病症的用途
EP3816185A1 (de) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispezifischer antikörper gegen pd-l1 und ein tumorassoziiertes antigen
WO2021116119A1 (en) 2019-12-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
IL294571A (en) 2020-01-10 2022-09-01 Inst Nat Sante Rech Med rspo1 proteins and their uses
CN114929261A (zh) 2020-02-17 2022-08-19 生物测试股份公司 凝血因子viii的皮下施用
EP4149558A1 (de) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
EP3915580A1 (de) 2020-05-29 2021-12-01 Numab Therapeutics AG Multispezifischer antikörper
EP4153636A1 (de) 2020-06-29 2023-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Einzeldomänenantikörper gegen protein s und polypeptide damit
EP3988568A1 (de) 2020-10-21 2022-04-27 Numab Therapeutics AG Kombinationsbehandlung
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
US20240067758A1 (en) 2020-12-07 2024-02-29 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
WO2022130182A1 (en) 2020-12-14 2022-06-23 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
JP2024504471A (ja) 2021-02-02 2024-01-31 ヌマブ セラピューティックス アーゲー Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
JP2024506070A (ja) 2021-02-15 2024-02-08 アフィボディ アクティエボラーグ 新規ｈｅｒ２結合ポリペプチド
CN117321076A (zh) 2021-02-19 2023-12-29 美国卫生及公众服务部代表 中和SARS-CoV-2的单结构域抗体
WO2023052541A1 (en) 2021-09-30 2023-04-06 Imcheck Therapeutics Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
EP4183800A1 (de) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Neue sars-cov-2-neutralisierende antikörper
WO2023187657A1 (en) 2022-03-30 2023-10-05 Novartis Ag Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
WO2024056668A1 (en) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
WO2024074498A1 (en) 2022-10-04 2024-04-11 Imcheck Therapeutics Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4666884A (en) * 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
SE8505922D0 (sv) * 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
US5095096A (en) * 1987-05-29 1992-03-10 Sagami Chemical Research Center Fused protein comprising lymphotoxin
GB8728856D0 (en) * 1987-12-10 1988-01-27 Bradwell A R Tumour-locating agents & method of locating tumours

Also Published As

Publication number Publication date
JPH04507242A (ja) 1992-12-17
DE69010206D1 (de) 1994-07-28
CA2064689C (en) 2002-04-30
EP0486525B1 (de) 1994-06-22
JP3477196B2 (ja) 2003-12-10
ATE107514T1 (de) 1994-07-15
SE8902638D0 (sv) 1989-08-01
WO1991001743A1 (en) 1991-02-21
AU6143990A (en) 1991-03-11
SE8902638L (sv) 1991-02-02
AU652124B2 (en) 1994-08-18
EP0486525A1 (de) 1992-05-27
SE509359C2 (sv) 1999-01-18
CA2064689A1 (en) 1991-02-02

Similar Documents

Publication Publication Date Title
ATE107514T1 (de) Stabilisierte protein- oder peptidkonjugate.
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
DK642587D0 (da) Insulinpraeparat
NO940663L (no) Lyofilisert polyalkylenoksid modifisert protein og polypeptid komplekser med cyclodextrin
IL97411A (en) Pharmaceutical formulations comprising hapten-modified diagnostic or therapeutic agents
ATE235513T1 (de) Opioid-konjugate mit endogenen trägerproteinen
DK0751781T3 (da) Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme
HU906177D0 (en) Process for the production of peptide derivatives and medical and diagnostical preparations containing such derivatives
DE68925974T2 (de) Konjugate zur steigerung der durchlässigkeit der gefässe
NO993866L (no) Legemiddel mot lymfatiske tumorer
CA2295199A1 (en) Method for treating vascular proliferative diseases with p27 and fusions thereof
RU2002130203A (ru) Пептидные конъюгаты для доставки лекарственного средства
RU97105374A (ru) Модифицированные белки
CA2154080A1 (en) Novel anticoagulant cofactor activity
ATE144149T1 (de) Therapeutisches verfahren zur behandlung von iddm
NZ332829A (en) Use of a polypeptide corresponding to a serine threonine kinase receptor, ALK-7 for neurological diseases
NZ234173A (en) Alpha-melanocyte stimulating hormone derivative (alphamsh)-targetted moiety conjugate
IL101675A0 (en) Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
DE69129463T2 (de) Verwendung von substanzen in partikelform
AU1200488A (en) Protein c inhibitor (pci) as pharmaceutical and in vitro diagnostic aid, a process for the preparation of a pharmaceutical or diagnostic aid of this type, and an agent containing pci
NZ234937A (en) Diagnostic reagent comprising a labelled antibody against a fibrinolytic enzyme and its use in detection of an enzyme associated with thromboses
AU2459188A (en) Anticoagulative protein pp4-x, and its preparation and use
WO1997035884A8 (en) Improved production of antibodies through the use of combinations of antigen and antibody, test kits incorporating said antibodies, and medical uses of said antibodies
PT999849E (pt) Utilizacao de lbp no tratamento da septicemia

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AFFIBODY TECHNOLOGY SWEDEN AB, STOCKHOLM, SE

8327 Change in the person/name/address of the patent owner

Owner name: AFFIBODY AB, BROMMA, SE

8327 Change in the person/name/address of the patent owner

Owner name: AFFIBODY AB, BROMMA, SE